DE:H5O0 Stock Latest News
Company AnnouncementsArgent BioPharma Licenses Non-Core Cannabis Genetics in Global Deal with Thai Phytomed6d ago
Company AnnouncementsArgent Biopharma sharpens immune focus and monetises CannEpil with new licensing deals1w ago
Company AnnouncementsArgent BioPharma Sets November Date for Annual General Meeting2w ago
Company AnnouncementsArgent BioPharma Sets AGM Date and Director Nomination Deadline2w ago
Company AnnouncementsArgent BioPharma Refines Immune Modulation Strategy Around Inflammation and Healthy Ageing3w ago
Company AnnouncementsArgent Biopharma Seeks ASX Quotation for 1.25 Million New Shares1M ago
Company AnnouncementsArgent BioPharma Narrows Annual Loss After Restructuring and Cost Controls2M ago
Company AnnouncementsArgent Biopharma Details Governance Compliance in ASX Filing2M ago
Company AnnouncementsArgent BioPharma Secures FDA-CVM INAD for CannEpil Veterinary Cancer-Pain Program2M ago- Company AnnouncementsArgent Biopharma Plans Options and Convertible Notes Issue to Bolster Funding2M ago
Company AnnouncementsArgent BioPharma Advances CannEpil into U.S. Veterinary Market with New Development Program2M agoCompany AnnouncementsArgent Biopharma Options Expire Unexercised, Simplifying Capital Structure3M ago
- Company AnnouncementsArgent Biopharma Cuts Debt with CannEpil Deal and Expands Veterinary Pipeline3M ago
- Company AnnouncementsArgent BioPharma Secures Additional Convertible Note Funding and Updates Capital Structure3M ago
Company AnnouncementsArgent Biopharma Issues 385,000 New Convertible Notes on ASX3M ago- Company AnnouncementsArgent Biopharma Plans New Unlisted Options Issue on ASX3M ago
Company AnnouncementsArgent BioPharma Draws A$350,000 Under Convertible Funding Deal3M agoCompany AnnouncementsArgent BioPharma Strikes Global CannEpil Licensing Deal to Wipe Out Secured Debt3M ago
